Cover Image
Market Research Report

Global Cancer Monoclonal Antibodies Market Size study, by Type, by Therapies (Bevacizumab, Rituximab, Trastuzumab, Cetuximab, Panitumumab, Others), by Application and Regional Forecasts 2020-2027

Published by Bizwit Research & Consulting LLP Product code 943634
Published Content info
Delivery time: 2-3 business days
Price
Back to Top
Global Cancer Monoclonal Antibodies Market Size study, by Type, by Therapies (Bevacizumab, Rituximab, Trastuzumab, Cetuximab, Panitumumab, Others), by Application and Regional Forecasts 2020-2027
Published: June 5, 2020 Content info:
Description

Title:
Global Cancer Monoclonal Antibodies Market Size study, by Type (Murine Antibodies, Chimeric Antibodies, Humanized Antibodies), by Therapies (Bevacizumab (Avastin), Rituximab (Rituxan), Trastuzumab (Herceptin), Cetuximab (Erbitux), Panitumumab (Vectibix), Others), by Application (Breast Cancer, Blood Cancer, Liver Cancer, Brain Cancer, Colorectal Cancer, Others) and Regional Forecasts 2020-2027.

Global Cancer Monoclonal Antibodies Market is valued at approximately USD 41.3 billion in 2019 and is anticipated to grow with a healthy growth rate of more than 11.3% over the forecast period 2020-2027. Cancer monoclonal antibodies is a type of laboratory-produced molecules which is being serve as substitute antibodies that can improve, restore, or simulate the immune system's raid on cancer cells. They are primarily intended to bind to antigens which are usually more in the amount on the surface of cancer cells than healthy cells. They can be used in the treatment of several types of cancer, including brain cancer, breast cancer, lung cancer, melanoma, and many more, thus accelerating the growth of cancer monoclonal antibodies market around the world. Further, increasing prevalence of cancer, rising investments & funding in research & development of genomic studies, and technological enhancements in genetic sequencing and target gene selection are the few factors responsible for the high CAGR of the market during the forecast period. Cancer is the one of the major causes of death around the world. According to the International Agency for Research on Cancer (IARC), in 2018, there were around 17.0 million new cancer cases and 9.5 million cancer deaths registered throughout the world. Also, the prevalence of cancer around the world is expected to grow to almost 27.5 million new cancer cases and 16.3 million cancer deaths by the year 2040. This, in turn, is expected to augment the demand for cancer monoclonal antibodies around the world. Amidst the COVID-19 outbreak around the world, the pharma industry is more concerned about the development of the COVID-19 vaccine, thus, R&D efforts for cancer monoclonal antibodies is substantially decline. Though, the demand for cancer monoclonal antibodies is not affecting, and it is high as much as before the COVID-19 crisis. Therefore, the market will boost at a significant rate in the upcoming years. However, stringent regulatory guidelines and long duration of R&D with rising failures in clinical trials are the few factors impeding the market growth during the forecast period of 2020-2027.

The regional analysis of the global Cancer Monoclonal Antibodies market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the leading/significant region across the world in terms of market share owing to the increasing cases of cancer among people, along with the rising government expenditure for infection control and management in the region. Whereas, North America is also anticipated to exhibit the highest growth rate / CAGR over the forecast period 2020-2027. Factors such as rising government funding for cancer research & technology, followed by the availability of a significant number of market players would create lucrative growth prospects for the Cancer Monoclonal Antibodies market across the Asia-Pacific region.

Major market player included in this report are:

Amgen Inc.

Bristol Myers Squibb Company

Eli Lilly and Company

F. Hoffmann-La Roche Ltd

Genmab AS

GlaxoSmithKline PLC

Johnson & Johnson

Novartis AG

Merck & Co., Inc

Spectrum Pharmaceuticals Inc.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Type:

Murine Antibodies

Chimeric Antibodies

Humanized Antibodies

By Therapies:

Bevacizumab (Avastin)

Rituximab (Rituxan)

Trastuzumab (Herceptin)

Cetuximab (Erbitux)

Panitumumab (Vectibix)

Others

By Application:

Breast Cancer

Blood Cancer

Liver Cancer

Brain Cancer

Colorectal Cancer

Others

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2017, 2018

Base year - 2019

Forecast period - 2020 to 2027

Target Audience of the Global Cancer Monoclonal Antibodies Market in Market Study:

Key Consulting Companies & Advisors

Large, medium-sized, and small enterprises

Venture capitalists

Value-Added Resellers (VARs)

Third-party knowledge providers

Investment bankers

Investors

Table of Contents

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2018-2027 (USD Billion)
    • 1.2.1. Cancer Monoclonal Antibodies Market, by Region, 2018-2027 (USD Billion)
    • 1.2.2. Cancer Monoclonal Antibodies Market, by Type, 2018-2027 (USD Billion)
    • 1.2.3. Cancer Monoclonal Antibodies Market, by Therapies, 2018-2027 (USD Billion)
    • 1.2.4. Cancer Monoclonal Antibodies Market, by Application, 2018-2027 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Cancer Monoclonal Antibodies Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Cancer Monoclonal Antibodies Market Dynamics

  • 3.1. Cancer Monoclonal Antibodies Market Impact Analysis (2018-2027)
    • 3.1.1. Market Drivers
    • 3.1.2. Market Challenges
    • 3.1.3. Market Opportunities

Chapter 4. Global Cancer Monoclonal Antibodies Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
    • 4.1.6. Futuristic Approach to Porter's 5 Force Model (2017-2027)
  • 4.2. PEST Analysis
    • 4.2.1. Political
    • 4.2.2. Economical
    • 4.2.3. Social
    • 4.2.4. Technological
  • 4.3. Investment Adoption Model
  • 4.4. Analyst Recommendation & Conclusion

Chapter 5. Global Cancer Monoclonal Antibodies Market, by Type

  • 5.1. Market Snapshot
  • 5.2. Global Cancer Monoclonal Antibodies Market by Type, Performance - Potential Analysis
  • 5.3. Global Cancer Monoclonal Antibodies Market Estimates & Forecasts by Type 2017-2027 (USD Billion)
  • 5.4. Cancer Monoclonal Antibodies Market, Sub Segment Analysis
    • 5.4.1. Murine Antibodies
    • 5.4.2. Chimeric Antibodies
    • 5.4.3. Humanized Antibodies

Chapter 6. Global Cancer Monoclonal Antibodies Market, by Therapies

  • 6.1. Market Snapshot
  • 6.2. Global Cancer Monoclonal Antibodies Market by Therapies, Performance - Potential Analysis
  • 6.3. Global Cancer Monoclonal Antibodies Market Estimates & Forecasts by Therapies 2017-2027 (USD Billion)
  • 6.4. Cancer Monoclonal Antibodies Market, Sub Segment Analysis
    • 6.4.1. Bevacizumab (Avastin)
    • 6.4.2. Rituximab (Rituxan)
    • 6.4.3. Trastuzumab (Herceptin)
    • 6.4.4. Cetuximab (Erbitux)
    • 6.4.5. Panitumumab (Vectibix)
    • 6.4.6. Others

Chapter 7. Global Cancer Monoclonal Antibodies Market, by Application

  • 7.1. Market Snapshot
  • 7.2. Global Cancer Monoclonal Antibodies Market by Application - Potential Analysis
  • 7.3. Global Cancer Monoclonal Antibodies Market Estimates & Forecasts by Application 2017-2027 (USD Billion)
  • 7.4. Cancer Monoclonal Antibodies Market, Sub Segment Analysis
    • 7.4.1. Breast Cancer
    • 7.4.2. Blood Cancer
    • 7.4.3. Liver Cancer
    • 7.4.4. Brain Cancer
    • 7.4.5. Colorectal Cancer
    • 7.4.6. Others

Chapter 8. Global Cancer Monoclonal Antibodies Market, Regional Analysis

  • 8.1. Cancer Monoclonal Antibodies Market, Regional Market Snapshot
  • 8.2. North America Cancer Monoclonal Antibodies Market
    • 8.2.1. U.S. Cancer Monoclonal Antibodies Market
      • 8.2.1.1. Type breakdown estimates & forecasts, 2017-2027
      • 8.2.1.2. Therapies breakdown estimates & forecasts, 2017-2027
      • 8.2.1.3. Application breakdown estimates & forecasts, 2017-2027
    • 8.2.2. Canada Cancer Monoclonal Antibodies Market
  • 8.3. Europe Cancer Monoclonal Antibodies Market Snapshot
    • 8.3.1. U.K. Cancer Monoclonal Antibodies Market
    • 8.3.2. Germany Cancer Monoclonal Antibodies Market
    • 8.3.3. France Cancer Monoclonal Antibodies Market
    • 8.3.4. Spain Cancer Monoclonal Antibodies Market
    • 8.3.5. Italy Cancer Monoclonal Antibodies Market
    • 8.3.6. Rest of Europe Cancer Monoclonal Antibodies Market
  • 8.4. Asia-Pacific Cancer Monoclonal Antibodies Market Snapshot
    • 8.4.1. China Cancer Monoclonal Antibodies Market
    • 8.4.2. India Cancer Monoclonal Antibodies Market
    • 8.4.3. Japan Cancer Monoclonal Antibodies Market
    • 8.4.4. Australia Cancer Monoclonal Antibodies Market
    • 8.4.5. South Korea Cancer Monoclonal Antibodies Market
    • 8.4.6. Rest of Asia Pacific Cancer Monoclonal Antibodies Market
  • 8.5. Latin America Cancer Monoclonal Antibodies Market Snapshot
    • 8.5.1. Brazil Cancer Monoclonal Antibodies Market
    • 8.5.2. Mexico Cancer Monoclonal Antibodies Market
  • 8.6. Rest of The World Cancer Monoclonal Antibodies Market

Chapter 9. Competitive Intelligence

  • 9.1. Top Market Strategies
  • 9.2. Company Profiles
    • 9.2.1. Amgen Inc.
      • 9.2.1.1. Key Information
      • 9.2.1.2. Overview
      • 9.2.1.3. Financial (Subject to Data Availability)
      • 9.2.1.4. Product Summary
      • 9.2.1.5. Recent Developments
    • 9.2.2. Bristol Myers Squibb Company
    • 9.2.3. Eli Lilly and Company
    • 9.2.4. F. Hoffmann-La Roche Ltd
    • 9.2.5. Genmab AS
    • 9.2.6. GlaxoSmithKline PLC
    • 9.2.7. Johnson & Johnson
    • 9.2.8. Novartis AG
    • 9.2.9. Merck & Co., Inc
    • 9.2.10. Spectrum Pharmaceuticals Inc.

Chapter 10. Research Process

  • 10.1. Research Process
    • 10.1.1. Data Mining
    • 10.1.2. Analysis
    • 10.1.3. Market Estimation
    • 10.1.4. Validation
    • 10.1.5. Publishing
  • 10.2. Research Attributes
  • 10.3. Research Assumption

LIST OF TABLES

  • TABLE 1. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET, REPORT SCOPE
  • TABLE 2. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY REGION 2017-2027 (USD BILLION)
  • TABLE 3. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY TYPE 2017-2027 (USD BILLION)
  • TABLE 4. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY THERAPIES 2017-2027 (USD BILLION)
  • TABLE 5. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY APPLICATION 2017-2027 (USD BILLION)
  • TABLE 6. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 7. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET BY REGION, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 8. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 9. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET BY REGION, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 10. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 11. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET BY REGION, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 12. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 13. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET BY REGION, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 14. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET BY SEGMENT, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 15. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET BY REGION, ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 16. U.S. CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 17. U.S. CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 18. U.S. CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 19. CANADA CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 20. CANADA CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 21. CANADA CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 22. UK CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 23. UK CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 24. UK CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 25. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 26. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 27. GERMANY CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 28. ROE CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 29. ROE CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 30. ROE CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 31. CHINA CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 32. CHINA CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 33. CHINA CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 34. INDIA CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 35. INDIA CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 36. INDIA CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 37. JAPAN CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 38. JAPAN CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 39. JAPAN CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 40. ROAPAC CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 41. ROAPAC CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 42. ROAPAC CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 43. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 44. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 45. BRAZIL CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 46. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 47. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 48. MEXICO CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 49. ROLA CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 50. ROLA CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 51. ROLA CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 52. ROW CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS, 2017-2027 (USD BILLION)
  • TABLE 53. ROW CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 54. ROW CANCER MONOCLONAL ANTIBODIES MARKET ESTIMATES & FORECASTS BY SEGMENT 2017-2027 (USD BILLION)
  • TABLE 55. LIST OF SECONDARY SOURCES, USED IN THE STUDY OF GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET
  • TABLE 56. LIST OF PRIMARY SOURCES, USED IN THE STUDY OF GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET
  • TABLE 57. YEARS CONSIDERED FOR THE STUDY
  • TABLE 58. EXCHANGE RATES CONSIDERED

LIST OF FIGURES

  • FIG 1. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET, RESEARCH METHODOLOGY
  • FIG 2. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET, MARKET ESTIMATION TECHNIQUES
  • FIG 3. GLOBAL MARKET SIZE ESTIMATES & FORECAST METHODS
  • FIG 4. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET, KEY TRENDS 2019
  • FIG 5. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET, GROWTH PROSPECTS 2020-2027
  • FIG 6. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET, PORTERS 5 FORCE MODEL
  • FIG 7. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET, PEST ANALYSIS
  • FIG 8. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET, VALUE CHAIN ANALYSIS
  • FIG 9. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET BY SEGMENT, 2017 & 2027 (USD BILLION)
  • FIG 10. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET BY SEGMENT, 2017 & 2027 (USD BILLION)
  • FIG 11. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET BY SEGMENT, 2017 & 2027 (USD BILLION)
  • FIG 12. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET BY SEGMENT, 2017 & 2027 (USD BILLION)
  • FIG 13. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET BY SEGMENT, 2017 & 2027 (USD BILLION)
  • FIG 14. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET, REGIONAL SNAPSHOT 2017 & 2027
  • FIG 15. NORTH AMERICA CANCER MONOCLONAL ANTIBODIES MARKET 2017 & 2027 (USD BILLION)
  • FIG 16. EUROPE CANCER MONOCLONAL ANTIBODIES MARKET 2017 & 2027 (USD BILLION)
  • FIG 17. ASIA PACIFIC CANCER MONOCLONAL ANTIBODIES MARKET 2017 & 2027 (USD BILLION)
  • FIG 18. LATIN AMERICA CANCER MONOCLONAL ANTIBODIES MARKET 2017 & 2027 (USD BILLION)
  • FIG 19. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET, COMPANY MARKET SHARE ANALYSIS (2019)
Back to Top